Drunk shocks chippy staff with sausage supper after pulling down pants in shop dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and.
Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash runway into mid-2026.
By Denny Jacob Allakos shares dived 61% to $1.17 in premarket trading following news that it will halt lirentelimab-related activities across clinical,.
Allakos’s lirentelimab did not beat a placebo in separate Phase 2 tests in atopic dermatitis and spontaneous chronic urticaria. A restructuring now turns the biotech’s focus to an early-stage drug candidate also designed to treat inflammation.